|
Sign In to gain access to subscriptions and/or personal tools.
|
Achieving the goal of optimised renin system suppression: preclinical experience with a direct renin inhibitor
Friedrich C Luft
Medical Faculty of the Charité, Franz Volhard Clinic, HELIOS-Klinikum, Berlin, Germany, luft{at}fvk-berlin.de
Aliskiren is the first orally available direct renin inhibitor and is a highly potent and specific inhibitor of human renin.The high specificity for human renin has resulted in considerable challenges in utilising animal models in preclinical studies. Both marmoset and spontaneously hypertensive rat models demonstrate the safety and efficacy of aliskiren in reducing blood pressure, although both models have drawbacks.The former are difficult to study, while the latter feature a renin that is less amenable to inhibition by a human-renin-specific drug. However, a double transgenic rat (dTGR) model has been shown to be extremely valuable in preclinical studies of aliskiren.These rats are designed to express genes for human renin and angiotensinogen. Preclinical studies in dTGR demonstrate the efficacy and safety of aliskiren, both as monotherapy and in combination with ACE inhibitors and ARBs in the treatment of hypertension. Direct renin inhibition with aliskiren improves kidney function and reduces left ventricular hypertrophy, and may have the potential to provide end-organ protection.
Key Words: aliskiren • direct renin inhibitor • hypertension • animal models • preclinical studies
References
- Wood JM, Maibaum J., Rahuel J. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Azizi M., Webb R., Nussberger J., Hollenberg NK Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56.[Web of Science][Medline]
[Order article via Infotrieve]
- Weber MA, Giles TD Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med 2006;7:45-54.[Web of Science][Medline]
[Order article via Infotrieve]
- Wood JM, Schnell CR, Cumin F. et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23:417-26.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bohlender J., Fukamizu A., Lippoldt A. et al. High human renin hypertension in transgenic rats. Hypertension 1997;29:428-34.[Abstract/Free Full Text]
- Rigel DF, Fu F., Li S. et al. The renin inhibitor aliskiren is a potent and long-acting antihypertensive in double transgenic rats expressing human renin and angiotensinogen genes. J Am Coll Cardiol 2004;43(suppl A):483A. Abstract 1085.
- Pilz B., Shagdarusen E., Wellner M. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76.[Abstract/Free Full Text]
- Kehoe B., Keaton GR, Hill C. Elevated plasma renin activity associated with renal dysfunction. Nephron 1986;44:51-7.[Web of Science][Medline]
[Order article via Infotrieve]
- Malmqvist K., Ohman KP, Lind L. et al. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 2002;252:430-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Fischer R., Gapelyuk A., Schulz K. et al. Cardiac magnetic field mapping noninvasively monitors effects of electrical remodelling due to development of cardiac hypertrophy and fibrosis in double transgenic rats. Hypertension 2005;46;8489. Abstract P101.
- Shagdasuren E., Welner M., Breissen JH et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005;97:16-24.[Abstract/Free Full Text]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 2 suppl,
S12-S15 (2006)
DOI: 10.3317/jraas.2006.032
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
